LanZhou Foci PharmaceuticalLtd Crecimiento futuro

Future controles de criterios 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for LanZhou Foci PharmaceuticalLtd.

Información clave

n/a

Tasa de crecimiento de los beneficios

n/a

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Pharmaceuticals	19.3%
Tasa de crecimiento de los ingresos	n/a
Rentabilidad financiera futura	n/a
Cobertura de analistas	None
Última actualización	n/a

Actualizaciones recientes sobre el crecimiento futuro

No hay actualizaciones

Recent updates

Why LanZhou Foci PharmaceuticalLtd's (SZSE:002644) Shaky Earnings Are Just The Beginning Of Its Problems

Nov 01

These 4 Measures Indicate That LanZhou Foci PharmaceuticalLtd (SZSE:002644) Is Using Debt Reasonably Well

Aug 07

LanZhou Foci PharmaceuticalLtd's (SZSE:002644) Weak Earnings May Only Reveal A Part Of The Whole Picture

Apr 17

LanZhou Foci Pharmaceutical Co.,Ltd.'s (SZSE:002644) 26% Price Boost Is Out Of Tune With Earnings

Mar 13

LanZhou Foci Pharmaceutical Co.,Ltd.'s (SZSE:002644) 26% Price Boost Is Out Of Tune With Earnings

Mar 13

En esta sección solemos presentar previsiones de crecimiento de ingresos y beneficios basadas en las estimaciones por consenso de analistas profesionales para ayudar a los inversores a comprender la capacidad de la empresa para generar beneficios. Pero como LanZhou Foci PharmaceuticalLtd no ha proporcionado suficientes datos anteriores y no dispone de previsiones de analistas, sus beneficios futuros no pueden calcularse de forma fiable extrapolando datos anteriores o utilizando las previsiones de los analistas.

Es una situación poco común, ya que el 97% de las empresas disponibles en SimplyWall St sí disponen de datos financieros anteriores.

Previsiones de crecimiento de beneficios e ingresos

SZSE:002644 - Estimaciones futuras de los analistas y datos financieros pasados (CNY Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
9/30/2024	989	46	86	108	N/A
6/30/2024	1,036	46	66	90	N/A
3/31/2024	1,119	62	45	54	N/A
12/31/2023	1,163	67	43	66	N/A
9/30/2023	1,227	116	52	85	N/A
6/30/2023	1,206	115	-23	7	N/A
3/31/2023	1,124	111	0	56	N/A
1/1/2023	1,042	109	45	87	N/A
9/30/2022	852	75	-133	-123	N/A
6/30/2022	893	97	-25	2	N/A
3/31/2022	877	92	-14	9	N/A
1/1/2022	818	93	-21	12	N/A
9/30/2021	830	71	40	155	N/A
6/30/2021	726	58	-23	85	N/A
3/31/2021	708	118	-37	78	N/A
12/31/2020	668	108	-60	63	N/A
9/30/2020	664	110	-29	41	N/A
6/30/2020	646	128	11	84	N/A
3/31/2020	611	75	0	68	N/A
12/31/2019	629	75	-45	48	N/A
9/30/2019	607	90	-106	21	N/A
6/30/2019	583	76	-93	38	N/A
3/31/2019	558	65	-162	41	N/A
12/31/2018	545	74	-224	37	N/A
9/30/2018	581	79	-342	47	N/A
6/30/2018	552	82	N/A	43	N/A
3/31/2018	543	83	N/A	41	N/A
12/31/2017	501	74	N/A	66	N/A
9/30/2017	420	66	N/A	14	N/A
6/30/2017	405	65	N/A	39	N/A
3/31/2017	377	65	N/A	59	N/A
12/31/2016	363	61	N/A	57	N/A
9/30/2016	337	57	N/A	96	N/A
6/30/2016	345	54	N/A	85	N/A
3/31/2016	339	46	N/A	69	N/A
12/31/2015	328	43	N/A	64	N/A
9/30/2015	334	40	N/A	53	N/A
6/30/2015	346	38	N/A	58	N/A
3/31/2015	371	35	N/A	94	N/A
12/31/2014	399	35	N/A	94	N/A
9/30/2014	384	34	N/A	77	N/A
6/30/2014	358	33	N/A	65	N/A
3/31/2014	319	31	N/A	17	N/A
12/31/2013	292	31	N/A	-10	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Insufficient data to determine if 002644's forecast earnings growth is above the savings rate (2.9%).

Beneficios vs. Mercado: Insufficient data to determine if 002644's earnings are forecast to grow faster than the CN market

Beneficios de alto crecimiento: Insufficient data to determine if 002644's earnings are expected to grow significantly over the next 3 years.

Ingresos vs. Mercado: Insufficient data to determine if 002644's revenue is forecast to grow faster than the CN market.

Ingresos de alto crecimiento: Insufficient data to determine if 002644's revenue is forecast to grow faster than 20% per year.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Insufficient data to determine if 002644's Return on Equity is forecast to be high in 3 years time

LanZhou Foci PharmaceuticalLtd Crecimiento futuro

Future controles de criterios 0/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Why LanZhou Foci PharmaceuticalLtd's (SZSE:002644) Shaky Earnings Are Just The Beginning Of Its Problems

Third quarter 2024 earnings released: EPS: CN¥0.006 (vs CN¥0.004 in 3Q 2023)

LanZhou Foci Pharmaceutical Co.,Ltd. to Report Q3, 2024 Results on Oct 26, 2024

New minor risk - Earnings quality

High number of new directors

Second quarter 2024 earnings released: EPS: CN¥0.035 (vs CN¥0.058 in 2Q 2023)

LanZhou Foci Pharmaceutical Co.,Ltd. Announces Board Appointments

These 4 Measures Indicate That LanZhou Foci PharmaceuticalLtd (SZSE:002644) Is Using Debt Reasonably Well

LanZhou Foci Pharmaceutical Co.,Ltd. to Report First Half, 2024 Results on Aug 27, 2024

Dividend reduced to CN¥0.03

LanZhou Foci PharmaceuticalLtd's (SZSE:002644) Weak Earnings May Only Reveal A Part Of The Whole Picture

Investor sentiment deteriorates as stock falls 16%

First quarter 2024 earnings released: EPS: CN¥0.036 (vs CN¥0.054 in 1Q 2023)

LanZhou Foci Pharmaceutical Co.,Ltd., Annual General Meeting, Apr 30, 2024

LanZhou Foci Pharmaceutical Co.,Ltd. to Report Q1, 2024 Results on Apr 25, 2024

LanZhou Foci Pharmaceutical Co.,Ltd.'s (SZSE:002644) 26% Price Boost Is Out Of Tune With Earnings

LanZhou Foci Pharmaceutical Co.,Ltd.'s (SZSE:002644) 26% Price Boost Is Out Of Tune With Earnings

Investor sentiment improves as stock rises 15%

Investor sentiment deteriorates as stock falls 18%

Less than half of directors are independent

LanZhou Foci Pharmaceutical Co.,Ltd. to Report Fiscal Year 2023 Results on Apr 10, 2024

Third quarter 2023 earnings released: EPS: CN¥0.004 (vs CN¥0.003 in 3Q 2022)

Second quarter 2023 earnings released: EPS: CN¥0.058 (vs CN¥0.059 in 2Q 2022)

LanZhou Foci Pharmaceutical Co.,Ltd. to Report First Half, 2023 Results on Aug 03, 2023

Lanzhou Foci Pharmaceutical Co.,Ltd. Announces Final Dividend on A Shares for the Year 2022, Payable on June 15, 2023

First quarter 2023 earnings released: EPS: CN¥0.054 (vs CN¥0.042 in 1Q 2022)

Investor sentiment improves as stock rises 18%

Investor sentiment deteriorated over the past week

High number of new and inexperienced directors

Third quarter 2022 earnings released: EPS: CN¥0.003 (vs CN¥0.047 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.059 (vs CN¥0.05 in 2Q 2021)

Lanzhou Foci Pharmaceutical Co.,Ltd. Announces Final Dividend on A Shares for the Year 2021, Payable on May 27, 2022

High number of new and inexperienced directors

Investor sentiment deteriorated over the past week

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.047 (vs CN¥0.021 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.05 (vs CN¥0.17 in 2Q 2020)

Full year 2020 earnings released: EPS CN¥0.22 (vs CN¥0.15 in FY 2019)

LanZhou Foci Pharmaceutical Co.,Ltd. to Report Fiscal Year 2020 Results on Mar 25, 2021

New 90-day low: CN¥6.81

New 90-day low: CN¥7.14

New 90-day low: CN¥7.57

New 90-day low: CN¥7.59

Third quarter earnings released

LanZhou Foci Pharmaceutical Co.,Ltd. to Report Q3, 2020 Results on Oct 21, 2020

New 90-day low: CN¥7.75

New 90-day low - CN¥7.92

First half earnings released

LanZhou Foci Pharmaceutical Co.,Ltd. to Report First Half, 2020 Results on Aug 27, 2020

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento